Literature DB >> 11345196

Molecular biology of chronic myeloid leukemia.

Y Maru1.   

Abstract

Multistep carcinogenesis is exemplified by chronic myeloid leukemia with clinical manifestation consisting of a chronic phase and blast crisis. Pathological generation of BCR-ABL (breakpoint cluster region-Abelson) results in growth promotion, differentiation, resistance to apoptosis, and defect in DNA repair in targeted blood cells. Domains in BCR and ABL sequences work in concert to elicit a variety of leukemogenic signals including Ras, STAT5 (signal transducer and activator of transcription-5), Myc, cyclin D1, P13 (phosphatidylinositol 3-kinase), RIN1 (Ras interaction/interference), and activation of actin cytoskeleton. However, the mechanism of differentiation of transformed cells is poorly understood. A mutator phenotype of BCR-ABL could explain the transformation to blast crisis. The aim of this review is to integrate molecular and biological information on BCR, ABL, and BCR-ABL and to focus on how signaling from those molecules mirrors the biological phenotypes of chronic myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11345196     DOI: 10.1007/BF02981955

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  205 in total

1.  The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

Authors:  A J Ridley; A Hall
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

Authors:  F van Rhee; A Hochhaus; F Lin; J V Melo; J M Goldman; N C Cross
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

3.  Pleckstrin domain homology.

Authors:  R J Haslam; H B Koide; B A Hemmings
Journal:  Nature       Date:  1993-05-27       Impact factor: 49.962

4.  The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl.

Authors:  P Dupraz; N Rebai; S J Klein; N Beaulieu; P Jolicoeur
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

6.  c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein.

Authors:  J Zhu; S K Shore
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

7.  Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

Authors:  M Wetzler; M Talpaz; R A Van Etten; C Hirsh-Ginsberg; M Beran; R Kurzrock
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.

Authors:  M Towatari; K Adachi; H Kato; H Saito
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

9.  Human ABR encodes a protein with GAPrac activity and homology to the DBL nucleotide exchange factor domain.

Authors:  N Heisterkamp; V Kaartinen; S van Soest; G M Bokoch; J Groffen
Journal:  J Biol Chem       Date:  1993-08-15       Impact factor: 5.157

10.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

View more
  11 in total

1.  Acute lymphoblastic leukemia with t(1;9;22)(q32;q34;q11).

Authors:  Shin Fujisawa; Heiwa Kanamori; Maki Takabayashi; Masatsugu Tanaka; Satoshi Yamaji; Naoto Tomita; Katsumichi Fujimaki; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

2.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

3.  Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs).

Authors:  Yijun Ruan; Hong Sain Ooi; Siew Woh Choo; Kuo Ping Chiu; Xiao Dong Zhao; K G Srinivasan; Fei Yao; Chiou Yu Choo; Jun Liu; Pramila Ariyaratne; Wilson G W Bin; Vladimir A Kuznetsov; Atif Shahab; Wing-Kin Sung; Guillaume Bourque; Nallasivam Palanisamy; Chia-Lin Wei
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

4.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Authors:  Agata Klejman; Steven J Schreiner; Malgorzata Nieborowska-Skorska; Artur Slupianek; Matthew Wilson; Thomas E Smithgall; Tomasz Skorski
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

5.  Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.

Authors:  Noriko Doki; Jiro Kitaura; Tomoyuki Uchida; Daichi Inoue; Yuki Kagiyama; Katsuhiro Togami; Masamichi Isobe; Shinichi Ito; Akie Maehara; Kumi Izawa; Naoko Kato; Toshihiko Oki; Yuka Harada; Fumio Nakahara; Hironori Harada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2011-12-22       Impact factor: 2.490

6.  PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.

Authors:  Kevin J Johnson; Amy R Peck; Chengbao Liu; Thai H Tran; Fransiscus E Utama; Ashley B Sjolund; John D Schaber; Agnieszka K Witkiewicz; Hallgeir Rui
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

7.  Multiple roles and therapeutic implications of Akt signaling in cancer.

Authors:  Emiliano Calvo; Victoria Bolós; Enrique Grande
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 8.  Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.

Authors:  Takumi Era
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

9.  Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.

Authors:  Toshio Nishihara; Yasuo Miura; Yumi Tohyama; Chisato Mizutani; Terutoshi Hishita; Satoshi Ichiyama; Takashi Uchiyama; Kaoru Tohyama
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

10.  Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family.

Authors:  Patrick Viatour; Tim C Somervaille; Shivkumar Venkatasubrahmanyam; Scott Kogan; Margaret E McLaughlin; Irving L Weissman; Atul J Butte; Emmanuelle Passegué; Julien Sage
Journal:  Cell Stem Cell       Date:  2008-10-09       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.